A firming and anti-wrinkle composition, its preparation method and use

Abstract

The present application belongs to the technical field of cosmetics, and discloses a firming and anti-wrinkle composition, a preparation method and application thereof.The composition comprises the following components: Kluyveromyces lactis lactic acid bacteria / Ganoderma lucidum fermentation filtrate, sodium mannose phosphate and oligopeptide.The composition of the present application plays an inhibitory role in various aspects of skin relaxation and aging through the synergistic effect of Kluyveromyces lactis lactic acid bacteria / Ganoderma lucidum fermentation filtrate, sodium mannose phosphate and oligopeptide, from the three key paths of enhancing cell vitality, promoting tissue renewal and healing, and promoting collagen production, to achieve the purpose of comprehensive and efficient firming and anti-wrinkling.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, and specifically relates to a firming and anti-wrinkle composition, its preparation method, and its application. Background Technology

[0002] Aging is a series of chronic, progressive degenerative changes in morphology, structure, and physiological function that occur in organisms as they age. Aging is a natural law of life, an inevitable and irreversible process for all living organisms. External manifestations of skin aging include: sagging skin, wrinkles, dryness, thinning, and pigmentation; internal manifestations include: reduced cell vitality, collagen loss, and damage to the skin barrier. Although skin aging is irreversible, targeted use of anti-aging cosmetics can help delay its progression.

[0003] Existing anti-aging cosmetics mainly focus on promoting collagen production, which has some effect, but its effects are relatively limited. To achieve better anti-aging effects, it is necessary to start from the principles of skin aging and intervene in multiple causes of skin aging, such as improving cell vitality, repairing the skin barrier, and promoting collagen production, in order to better delay skin aging. Summary of the Invention

[0004] The present invention aims to at least solve one of the technical problems existing in the prior art. To this end, the present invention provides a firming and anti-wrinkle composition, its preparation method, and its application. This composition exerts an inhibitory effect on all aspects of skin laxity and aging through three key pathways: enhancing cell vitality, promoting tissue renewal and healing, and promoting collagen production, thereby achieving a comprehensive and efficient firming and anti-wrinkle effect.

[0005] In a first aspect, the present invention provides a composition comprising: Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate, and oligopeptides.

[0006] Specifically, the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate is obtained by fermenting Ganoderma lucidum extract with Kluyveromyces lactis. Currently, most commercially available Ganoderma lucidum extracts use Ganoderma lucidum var. rubrum as raw material, with fewer using Ganoderma lucidum var. rubrum. However, Ganoderma lucidum var. rubrum and Ganoderma lucidum var. rubrum have significant differences in chemical composition. The main component of Ganoderma lucidum var. rubrum is highly oxidized lanosterol compounds, while Ganoderma lucidum var. rubrum consists of aromatic terpenes, ergosterols, and alkaloids. Ganoderma lucidum from different sources also has certain differences in its corresponding effects. The Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate used in this invention can significantly promote COL-1 synthesis and reduce MMP-1 production, exhibiting excellent firming and anti-wrinkle effects.

[0007] Specifically, sodium mannose phosphate participates in the metabolism of substances and energy, providing the material and energy basis for biochemical processes, enhancing cell vitality, and thus achieving anti-aging at the cellular level.

[0008] Specifically, oligopeptides can shorten the healing time of damage, restore the skin barrier, and repair broken and aging elastic fiber networks, thereby increasing firmness and playing a role in tightening the skin, enhancing skin elasticity, and reducing wrinkles and anti-aging.

[0009] Specifically, the firming and anti-wrinkle effects of the composition of this invention are not achieved by randomly selecting and combining several ingredients. Instead, through in-depth research on the mechanisms of skin barrier repair and firming and anti-wrinkle action, and after numerous research experiments, three ingredients with corresponding effects were selected from a large number of ingredients: Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate, and oligopeptides. When combined, they have a synergistic effect, exerting an inhibitory effect on all aspects of skin laxity and aging through three key pathways: enhancing cell vitality, promoting tissue renewal and healing, and promoting collagen production, thereby achieving a comprehensive and efficient firming and anti-wrinkle effect.

[0010] In some embodiments of the present invention, the composition comprises, by weight parts: 0.1-95 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.003-0.15 parts of sodium mannose phosphate, and 0.0005-0.025 parts of oligopeptide.

[0011] In some embodiments of the present invention, the content of Ganoderma lucidum polysaccharides in the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate is ≥1.5 mg / mL.

[0012] In some embodiments of the present invention, the oligopeptide includes at least one of oligopeptide-1, oligopeptide-2, oligopeptide-3, oligopeptide-4, and oligopeptide-5.

[0013] A second aspect of the present invention provides a method for preparing the composition described in the first aspect of the present invention, comprising the following steps:

[0014] The filtrate of Kluyveromyces lactis / Ganoderma lucidum fermentation product, sodium mannose phosphate, and oligopeptides were mixed to obtain a composition.

[0015] A third aspect of the present invention provides a topical skin preparation comprising the composition described in the first aspect of the present invention.

[0016] In some embodiments of the present invention, the content of the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate in the topical skin preparation is 0.1-95 wt%.

[0017] In some embodiments of the present invention, the sodium mannose phosphate is present in a topical skin preparation at a content of 0.003-0.15 wt%.

[0018] In some embodiments of the present invention, the oligopeptide is present in a topical skin preparation at a content of 0.0005-0.025 wt%.

[0019] A fourth aspect of the present invention provides a cosmetic product comprising the composition described in the first aspect of the present invention.

[0020] In some embodiments of the present invention, the content of the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate in cosmetics is 0.1-95 wt%.

[0021] In some embodiments of the present invention, the sodium mannose phosphate content in the cosmetic is 0.003-0.15 wt%.

[0022] In some embodiments of the present invention, the oligopeptide is present in a cosmetic at a concentration of 0.0005-0.025 wt%.

[0023] In some embodiments of the present invention, the cosmetic further includes at least one of emulsifier, thickener, moisturizer, pH adjuster, preservative and fragrance.

[0024] In some embodiments of the present invention, the cosmetic includes any one of toner, serum, lotion, cream, or mask.

[0025] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0026] (1) The composition provided by the present invention, through the synergistic effect of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate and oligopeptides, exerts an inhibitory effect on all aspects of skin laxity and aging through three key pathways: enhancing cell vitality, promoting tissue renewal and healing, and promoting collagen production, thereby achieving a comprehensive and efficient firming and anti-wrinkle effect.

[0027] (2) The composition provided by the present invention is mild and non-irritating, which can enhance cell vitality, promote the production of COL-1, inhibit the production of MMP-1, effectively increase the water content of the skin, reduce transepidermal water loss, enhance skin elasticity and firmness, reduce wrinkles, and has excellent moisturizing, repairing and firming anti-wrinkle effects. Detailed Implementation

[0028] To enable those skilled in the art to more clearly understand the technical solutions described in this invention, the following embodiments are provided for illustration. It should be noted that the following embodiments do not constitute a limitation on the scope of protection claimed by this invention.

[0029] Unless otherwise specified, the raw materials, reagents or devices used in this invention can be obtained from conventional commercial sources or by existing known methods.

[0030] Example 1

[0031] A composition comprising the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.04 parts of sodium mannose phosphate, and 0.0025 parts of oligopeptide-1.

[0032] Example 2

[0033] A composition comprising the following components in parts by weight: 5 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.15 parts of sodium mannose phosphate, and 0.01 parts of oligopeptide-2.

[0034] Example 3

[0035] A composition comprising the following components in parts by weight: 95 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.003 parts of sodium mannose phosphate, and 0.0005 parts of oligopeptide-3.

[0036] Example 4

[0037] A composition comprising the following components in parts by weight: 0.1 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.003 parts of sodium mannose phosphate, and 0.025 parts of oligopeptide-4.

[0038] Example 5

[0039] A composition comprising the following components in parts by weight: 0.1 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.15 parts of sodium mannose phosphate, and 0.0005 parts of oligopeptide-5.

[0040] Comparative Example 1

[0041] A composition comprising the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate and 0.04 parts of sodium mannose phosphate.

[0042] Comparative Example 2

[0043] A composition comprising the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, and 0.0025 parts of oligopeptide-1.

[0044] Comparative Example 3

[0045] A composition comprising the following components in parts by weight: 0.04 parts sodium mannose phosphate and 0.0025 parts oligopeptide-1.

[0046] Comparative Example 4

[0047] One part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate.

[0048] Comparative Example 5

[0049] Sodium mannose phosphate 0.04 parts.

[0050] Comparative Example 6

[0051] Oligopeptide-1 0.0025 parts.

[0052] Comparative Example 7

[0053] A composition comprising the following components in parts by weight: 1 part Ganoderma lucidum extract, 0.04 parts sodium mannose phosphate, and 0.0025 parts oligopeptide-1.

[0054] Comparative Example 8

[0055] A composition comprising the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.04 parts of sodium mannose phosphate, and 0.0025 parts of acetyl hexapeptide-8.

[0056] Comparative Example 9

[0057] A composition comprising the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.04 parts of β-glucan, and 0.0025 parts of oligopeptide-1.

[0058] Application Example 1

[0059] A firming and anti-wrinkle toner containing the composition of Example 1, the formulation of which is shown in Table 1.

[0060] Table 1

[0061]

[0062]

[0063] The preparation method is as follows:

[0064] (1) Add phase A raw material to the mixing pot in sequence, heat to 60°C, and stir homogenously until dissolved;

[0065] (2) After heating the B phase raw material to 60°C until it melts and becomes transparent, add it to a mixing pot and disperse it evenly, then cool it down to 40°C;

[0066] (3) Add the C phase raw material to the mixing pot and stir to disperse it evenly;

[0067] (4) After the D phase raw material is evenly dispersed, it is added to the mixing pot and evenly dispersed. Then, the temperature is lowered to below 37°C to obtain the firming and anti-wrinkle lotion.

[0068] Application Example 2

[0069] A firming and anti-wrinkle facial mask containing the composition of Example 1, the formulation of which is shown in Table 2.

[0070] Table 2

[0071]

[0072]

[0073] The preparation method is as follows:

[0074] (1) Add phase A raw material to the mixing pot in sequence, heat to 60°C, and stir homogenously until dissolved;

[0075] (2) Add phase B raw material to the mixing pot and homogenize and disperse it evenly;

[0076] (3) After heating the C phase raw material to 60°C until it melts and becomes transparent, add it to a mixing pot and disperse it evenly, then cool it down to 40°C;

[0077] (3) Add the D phase raw material to the mixing pot and stir to disperse it evenly;

[0078] (4) After the E phase raw material is evenly dispersed, it is added to the mixing pot and evenly dispersed. Then, the temperature is lowered to below 37°C to obtain the firming and anti-wrinkle mask.

[0079] Application Example 3

[0080] A firming and anti-wrinkle lotion containing the composition of Example 1, the formulation of which is shown in Table 3.

[0081] Table 3

[0082]

[0083]

[0084] The preparation method is as follows:

[0085] (1) Add phase A raw material to the emulsifying pot in sequence, heat to 80°C, and stir homogenously to dissolve evenly;

[0086] (2) Add phase B raw material to the oil phase pot in sequence, heat to 80°C, stir and disperse evenly, then add to the emulsification pot, homogenize and emulsify, stir evenly and then cool down to 60°C.

[0087] (3) Add the C phase raw material to the emulsifying pot and homogenize and disperse it evenly;

[0088] (4) After heating the D phase raw material to 60°C until it melts and becomes transparent, add it to the emulsification pot and disperse it evenly, then cool it down to 40°C;

[0089] (5) After the E phase raw material is evenly dispersed, it is added to the emulsification pot and evenly dispersed. Then, the temperature is lowered to below 37°C to obtain the firming and anti-wrinkle emulsion.

[0090] Application Example 4

[0091] A firming and anti-wrinkle cream containing the composition of Example 1, the formulation of which is shown in Table 4.

[0092] Table 4

[0093]

[0094]

[0095] The preparation method is as follows:

[0096] (1) Add phase A raw material to the emulsifying pot in sequence, heat to 80°C, and stir homogenously to dissolve evenly;

[0097] (2) Add phase B raw material to the oil phase pot in sequence, heat to 80°C, stir and disperse evenly, then add to the emulsification pot, homogenize and emulsify, stir evenly and then cool down to 60°C.

[0098] (3) Add the C phase raw material to the emulsifying pot and homogenize and disperse it evenly;

[0099] (4) After heating the D phase raw material to 60°C until it melts and becomes transparent, add it to the emulsification pot and disperse it evenly, then cool it down to 40°C;

[0100] (5) After the E phase raw material is evenly dispersed, it is added to the emulsification pot and evenly dispersed. Then, the temperature is lowered to below 37°C to obtain the firming and anti-wrinkle cream.

[0101] Comparative Application Example 1

[0102] The difference between this and Application Example 4 is that the cream in Application Example 1 does not contain the composition of Example 1, that is, it lacks Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate and oligopeptide-1. The other raw materials, contents and preparation methods are the same as in Application Example 4.

[0103] Comparative Application Example 2

[0104] The difference from Application Example 4 is that the cream in Comparative Application Example 2 replaces the composition of Example 1 with the composition of Comparative Example 1, that is, it lacks oligopeptide-1, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0105] Comparative Application Example 3

[0106] The difference from Application Example 4 is that the cream in Comparative Application Example 3 replaces the composition of Example 1 with the composition of Comparative Example 2, that is, it lacks sodium mannose phosphate, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0107] Comparative Application Example 4

[0108] The difference between this and Application Example 4 is that the cream in Application Example 4 replaces the composition of Example 1 with the composition of Comparative Example 3, i.e., it lacks the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0109] Comparative Application Example 5

[0110] The difference between this and Application Example 4 is that the cream in Comparative Application Example 5 replaces the composition of Example 1 with the components of Comparative Example 4, that is, it lacks sodium mannose phosphate and oligopeptide-1, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0111] Comparative Application Example 6

[0112] The difference between this and Application Example 4 is that the cream in Comparative Application Example 6 replaces the composition of Example 1 with the components of Comparative Example 5, that is, it lacks Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate and oligopeptide-1, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0113] Comparative Application Example 7

[0114] The difference from Application Example 4 is that the cream in Comparative Application Example 7 replaces the composition of Example 1 with the components of Comparative Example 6, that is, it lacks Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate and sodium mannose phosphate, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0115] Comparative Application Example 8

[0116] The difference from Application Example 4 is that the cream in Comparative Application Example 8 replaces the composition of Example 1 with the composition of Comparative Example 7, that is, the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate is replaced with an equal amount of Ganoderma lucidum extract, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0117] Comparative Application Example 9

[0118] The difference from Application Example 4 is that the cream in Comparative Application Example 9 replaces the composition of Example 1 with the composition of Comparative Example 8, that is, the oligopeptide-1 is replaced with an equal amount of acetyl hexapeptide-8, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0119] Comparative Application Example 10

[0120] The difference from Application Example 4 is that the cream in Comparative Application Example 10 replaces the composition of Example 1 with the composition of Comparative Example 9, that is, the sodium mannose phosphate is replaced with β-glucan in an equal amount, while the other raw materials, contents and preparation methods are the same as in Application Example 4.

[0121] Experimental Example 1: Red Blood Cell Hemolysis Test

[0122] The red blood cell hemolysis test (RBC) is an alternative to the rabbit eye irritation test (Draize test). Its basic principle is to evaluate the damage of chemicals to eye tissue cells by measuring the amount of hemoglobin dissolved and the degree of denaturation. Internationally, the RBC test is mainly used to evaluate the eye irritation of chemicals in cosmetics and raw materials.

[0123] The compositions of Examples 1-5 and the compositions or ingredients of Comparative Examples 1-9 were subjected to a red blood cell hemolysis test, which was conducted in accordance with the European Centre for Validation of Alternative Methods (ECVAM) RBC test method and grading standards. The ECVAM cosmetic product RBC irritation grading standards are shown in Table 5.

[0124] Table 5

[0125]

[0126]

[0127] The results of the red blood cell hemolysis experiment are shown in Table 6. In the table, L / D is the ratio of HD50 to DI, where HD50 is the sample concentration when 50% of red blood cells are hemolyzed, and DI is the protein denaturation index.

[0128] Table 6

[0129] Example 1 Non-irritating Example 2 Non-irritating Example 3 Non-irritating Example 4 Non-irritating Example 5 Non-irritating Comparative Example 1 Non-irritating Comparative Example 2 Non-irritating Comparative Example 3 Non-irritating Comparative Example 4 Non-irritating Comparative Example 5 Non-irritating Comparative Example 6 Non-irritating Comparative Example 7 Mild irritation Comparative Example 8 Non-irritating Comparative Example 9 Non-irritating

[0130] As can be seen from the results of the hemolysis experiment of red blood cells in Table 6, except for Comparative Example 7 which is slightly irritating, Examples 1-5 and Comparative Examples 1-6 and 8-9 are all non-irritating; indicating that the compositions of the present invention are all mild and non-irritating.

[0131] Experimental Example 2: Assay of Age-Related β-Galactosidase (SA-β-gal)

[0132] Human skin fibroblasts (HDF) were cultured in a 6-well plate at a rate of 1 × 10⁶ cells per well. 4 The cells were cultured at a density of 1,000 cells per cubic meter at 37°C with 5% CO2 for 24 hours. HDF was treated with the sample (5%) for 24 hours, followed by washing twice with phosphate-buffered saline (PBS) at 30 J / cm³. 2The cells were irradiated with UVB. Then, the PBS was removed, and the HDF containing the sample (5%) was incubated at 37°C with 5% CO2 for 24 hours. The cells were washed with 1 mL of PBS, then 0.5 mL of fixative was added, and the cells were incubated at room temperature for 15 minutes to fix them. 0.5 mL of mixed staining solution (470 μL staining solution, 5 μL staining replenishment solution, and 25 μL dimethylformamide containing 20 mg / mL X-gal) was added to the immobilized HDF, and the cells were incubated at 37°C for 24 hours to stain them. The stained cells were then washed with PBS, and 500 fibroblasts were randomly selected from each sample plate for microscopic photography. The SA-β-Gal stained fibroblasts were counted.

[0133] The relative ratio of senescent cells = (number of senescent cells in the sample / number of senescent cells in the model group) × 100%.

[0134] The compositions of Examples 1-5 and the compositions or components of Comparative Examples 1-9 were tested, and the results are shown in Table 7.

[0135] Table 7

[0136]

[0137]

[0138] As can be seen from the data in Table 7, the relative proportion of senescent cells in the compositions of Examples 1-5 is all below 53%, while the corresponding proportions in Comparative Examples 1-9 are all above 60%; this indicates that the compositions of the present invention have a good effect on improving cell vitality, and the components in the compositions have a synergistic effect, which can exert a better effect.

[0139] Analysis of type I collagen and matrix metalloproteinases in Experimental Case 3

[0140] HDF in a 6-well plate with 2×10 per well 4 The cells were cultured at a density of 1,000 cells per cubic meter at 37°C with 5% CO2 for 24 hours. HDF was treated with the sample (5%) for 24 hours, then washed twice with PBS and cultured at 30 J / cm². 2 The sample was irradiated with UVB. Then, the PBS was removed, and the sample (5%) was incubated in HDF at 37°C with 5% CO2 for 24 hours. After incubation, the levels of human type I collagen (COL-I) and matrix metalloproteinase-1 (MMP-1) were determined according to the ELISA kit instructions.

[0141] The compositions of Examples 1-5 and the compositions or components of Comparative Examples 1-9 were used to determine the content of human type I collagen and matrix metalloproteinases, and the results are shown in Table 8.

[0142] Table 8

[0143]

[0144]

[0145] Understandably, the higher the COL-1 content and the lower the MMP-1 content, the stronger the ability to promote collagen production, and the stronger the corresponding firming and anti-wrinkle ability.

[0146] As can be seen from the results in Table 8, the COL-1 content and MMP-1 content of each embodiment are better than those of Comparative Examples 1-9, indicating that the composition of the present invention has higher firming and anti-wrinkle ability and that the components in the composition have a synergistic effect.

[0147] Experimental Example 4: Test of Transdermal Water Loss in Humans

[0148] 110 healthy subjects were selected and randomly divided into 11 groups of 10 each. Application Example 4 and control Application Examples 1-10 were used as test samples. Subjects applied the sample to their face twice a day, morning and evening. Using a Corneometer CM825 skin moisture meter and an AF200 skin moisture loss meter, the facial moisture content and transepidermal water loss (TEWL) were measured before use (D0) and on day 28 (D28) under conditions of 21±1℃ and 50±10% humidity. After the subjects cleaned their faces and waited for 20 minutes, the corresponding change rates were calculated. The moisturizing and repairing effects of the product on human skin were comprehensively evaluated. The results are shown in Table 9.

[0149] Table 9

[0150]

[0151]

[0152] Understandably, a higher rate of change in water content indicates better moisturizing ability, and a greater decrease in the rate of change in TEWL indicates better repair ability.

[0153] As can be seen from the results in Table 9, compared with Comparative Application Examples 1-10, Application Example 4 showed better results in terms of both water content and transdermal water loss; indicating that cosmetics containing the composition of the present invention have better moisturizing and repairing effects.

[0154] Experimental Example 5: Human Body Firming Effect Test

[0155] 110 healthy subjects were selected and randomly divided into 11 groups of 10 each. Application Example 4 and control Application Examples 1-10 were used as test samples. Subjects applied the sample to their face twice a day, morning and evening. Using a Cutometer dual MPA580 skin elasticity tester, the elasticity-F4 value and elasticity-R2 value of the face were measured before use (D0) and on the 28th day of use (D28) under the conditions of temperature 21±1℃ and humidity 50±10%. The change rate of F4 value and R2 value was calculated to comprehensively evaluate the skin-tightening effect of the product. The results are shown in Table 10.

[0156] Table 10

[0157]

[0158]

[0159] Understandably, the F4 value and R2 value represent the firmness and elasticity of the skin, respectively. The greater the decrease in the rate of change of the F4 value and the greater the increase in the rate of change of the R2 value, the better the skin firmness and elasticity.

[0160] As can be seen from the results in Table 10, all values ​​of the sample using Application Example 4 are better than those of Comparative Application Examples 1-10; indicating that the cosmetic containing the composition of the present invention has a better firming effect.

[0161] Experimental Example 6: Anti-wrinkle effect test on human body

[0162] 110 healthy subjects were selected and randomly divided into 11 groups of 10 each. Application Example 4 and control Application Examples 1-10 were used as test samples. Subjects applied the sample to their face twice a day, morning and evening. Using a VISIA 7 image analyzer, before use (D0) and on day 28 (D28), under conditions of 21±1℃ and 50±10% humidity, the number of wrinkles and the total area of ​​wrinkles were measured after the subjects cleaned their faces and waited for 20 minutes. The corresponding rate of change was calculated to comprehensively evaluate the anti-wrinkle efficacy of the product on human skin. The results are shown in Table 11.

[0163] Table 11

[0164]

[0165]

[0166] As can be seen from the results in Table 11, the rate of change in the number of wrinkles and the rate of change in the total area of ​​wrinkles corresponding to the sample using Application Example 4 were both higher than those of the comparative Application Examples 1-10, indicating that its anti-wrinkle ability was better.

[0167] In summary, the composition of the present invention is mild and non-irritating, and its effects in moisturizing, repairing, firming, and anti-wrinkle are better than those of the comparative composition which lacks any one or two ingredients or is replaced with similar active ingredients. This indicates that the composition of the present invention is reasonably formulated and has a synergistic effect, which can significantly improve the moisturizing, repairing, firming, and anti-wrinkle effects.

[0168] The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention, and these equivalent modifications or substitutions are all included within the scope defined by the claims of this application.

Claims

1. A firming and anti-wrinkle composition, characterized in that, The composition comprises, by weight, the following components: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.04 parts of sodium mannose phosphate and 0.0025 parts of oligopeptide-1; The content of Ganoderma lucidum polysaccharides in the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate is ≥1.5 mg / mL.

2. The method for preparing the composition according to claim 1, characterized in that, Includes the following steps: The Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate, and oligopeptide-1 were mixed to obtain a composition.

3. A topical skin preparation, characterized in that, The topical skin preparation includes the composition of claim 1.

4. The topical skin preparation according to claim 3, characterized in that, The content of the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate is 0.1-95 wt%, the content of sodium mannose phosphate is 0.003-0.15 wt%, and the content of oligopeptide-1 is 0.0005-0.025 wt%.

5. A cosmetic product, characterized in that, The cosmetic product includes the composition according to claim 1.

6. The cosmetic product according to claim 5, characterized in that, The content of the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate is 0.1-95 wt%, the content of sodium mannose phosphate is 0.003-0.15 wt%, and the content of oligopeptide-1 is 0.0005-0.025 wt%.

7. The cosmetic product according to claim 5, characterized in that, The cosmetics also include at least one of the following: emulsifier, thickener, moisturizer, pH adjuster, preservative, and fragrance.

8. The cosmetic product according to claim 5, characterized in that, The cosmetic product is any one of the following: toner, serum, lotion, cream, or mask.

Images